News coverage about Viking Therapeutics (NASDAQ:VKTX) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viking Therapeutics earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.1172948602115 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Technical Secrets – Viking Therapeutics, Inc. (NASDAQ: VKTX) – Alpha Beta Stock (alphabetastock.com)
- Viking Therapeutics, Inc. (VKTX) Investors’ React on Long-Term Obligation – Stock News Stop (stockmarketstop.com)
- Viking Therapeutics, Inc. (NASDAQ:VKTX) – Glowing Stock’s Review – Nasdaq Journal (press release) (nasdaqjournal.com)
- Viking Therapeutics to Present at Biotech Showcase 2018 (prnewswire.com)
Shares of Viking Therapeutics (VKTX) traded up $0.01 during midday trading on Monday, reaching $5.01. The company’s stock had a trading volume of 806,000 shares, compared to its average volume of 1,122,300. The stock has a market capitalization of $146.40 and a price-to-earnings ratio of -5.89. Viking Therapeutics has a 52 week low of $0.88 and a 52 week high of $5.19.
Several analysts have recently commented on VKTX shares. Roth Capital set a $6.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 29th. Maxim Group set a $8.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a research report on Tuesday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Viking Therapeutics in a research report on Friday, November 10th. Finally, ValuEngine lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
COPYRIGHT VIOLATION NOTICE: This story was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://stocknewstimes.com/2018/01/08/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-viking-therapeutics-vktx-stock-price.html.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.